Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Firearm injury patients face measurable risk of bacterial infections

6

Aug 2026

Firearm injury patients face measurable risk of bacterial infections

A new study from researchers at the University of Maryland School of Medicine (UMSOM) found that bacterial infections develop in approximately 5 percent of adults hospitalized with firearm injuries, with most infections occurring during the initial hospitalization rather than after patients return home.

Nighttime light linked to conflicting signs of biological aging

6

Aug 2026

Nighttime light linked to conflicting signs of biological aging

Higher residential nighttime light exposure was associated with contrasting biological aging patterns in nearly 300,000 UK Biobank participants, depending on the aging algorithm used. PhenoAge and homeostatic dysregulation suggested a potentially adverse aging pattern, while KDM-BA showed the opposite association, underscoring uncertainty about how nighttime light relates to biological aging.

IL-6 receptor blockers show promise for preventing MOGAD relapses

6

Aug 2026

IL-6 receptor blockers show promise for preventing MOGAD relapses

An international study led by Mayo Clinic researchers has identified interleukin-6 (IL-6) receptor blockers as a promising option for preventing relapses in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). MOGAD is a rare autoimmune neurological disorder that can cause vision loss, paralysis and other serious neurological complications.

Early radionuclide therapy delays progression in metastatic prostate cancer

6

Aug 2026

Early radionuclide therapy delays progression in metastatic prostate cancer

Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.